You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Litigation Details for United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)


✉ Email this page to a colleague

« Back to Dashboard


United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)

Docket ⤷  Try a Trial Date Filed 2015-06-22
Court District Court, D. Massachusetts Date Terminated 2017-07-06
Cause 15:2 Antitrust Litigation Assigned To Allison Dale Burroughs
Jury Demand Plaintiff Referred To
Parties AFSCME HEALTH AND WELFARE FUND
Patents 6,894,051; 7,544,799; RE43,799; RE43,932
Attorneys Devona L. Wells
Firms Lockridge Grindal Nauen PLLP
Link to Docket External link to docket
Small Molecule Drugs cited in United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial and ⤷  Try a Trial .

Details for United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund v. Novartis Pharmaceuticals Corporation (D. Mass. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-06-22 1 application issued as U.S. Patent No. 6,894,051 (“the ’051 patent”). The ’051 patent expires on November 23… U.S. Patent No. 5,521,184 (“the ’184 Patent,” “the Zimmermann Patent,” or “the compound patent”), and…submitted all three patents (the ’184 patent, the ’051 patent, and the ’799 patent) to the FDA for listing…infringe the patent. 63. Patents are not bulletproof. To the contrary, patents are routinely…submit to the FDA the patent number and expiration date on a patent when the patent (1) “claims the drug External link to document
2016-04-08 106 ’097 application issued as U.S. Patent No. 6,894,051. The ’051 patent expires on November 23, 2019. … U.S. patent No. 5,521,184 (“the ’184 patent,” the “Zimmermann patent,” or the “compound patent”) and…submitted all three patents (the ’184 patent, the ’051 patent, and the ’799 patent) to the FDA for listing…infringe the patent. b. Patents are Not Bulletproof 65. Patents are not …submit to the FDA the patent number and expiration date on a patent when the patent (i) “claims the drug External link to document
2017-06-30 140 1) U.S. Patent No. 6,894,051 (“the ‘051 Patent”) issued on May 17, 2005, and (2) U.S. Patent No. 7,554,799…submitted all three patents—the original ‘184 Patent, the ‘051 Patent, and the ‘799 Patent—to the FDA to be…assignee of U.S. Patent No. 5,521,184 (“the ‘184 Patent”), which is the basic compound patent claiming Gleevec…of the ‘051 Patent. Plaintiffs allege that the ‘799 Patent was broader than the ‘051 Patent, which claimed…that the ‘051 Patent is invalid. The ‘799 Patent was eventually reissued as the RE’932 Patent. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.